Fahar Merchant, president and CEO of Protox, said: “Protox is very pleased to have completed this clinical trial ahead of schedule and looks forward to releasing top line data from this study in the fourth quarter of 2008.
“This Phase II study will provide Protox with valuable information as we continue to advance this exciting project that we believe has the potential of establishing a new standard of care for this disease.”